Antidiabetic effect of bio-enhanced preparation of turmeric in streptozotocin-nicotinamide induced type 2 diabetic Wistar rats.

Beta cell activity Curcumin Diabetes Insulin resistance Pancreas distribution Turmeric

Journal

Journal of Ayurveda and integrative medicine

ISSN: 0975-9476

Titre abrégé: J Ayurveda Integr Med

Pays: United States

ID NLM: 101551404

Informations de publication

Date de publication:

Historique:

received: 05 12 2020

revised: 06 04 2021

accepted: 11 04 2021

pubmed: 7 8 2021

medline: 7 8 2021

entrez: 6 8 2021

Statut: ppublish

Résumé

Poor oral bioavailability of curcumin, the active ingredient in turmeric, has limited its therapeutic use in various diseases including diabetes mellitus (DM). The present study was aimed at evaluating and comparing the antidiabetic activity as well as pharmacokinetic profile of two turmeric extracts. Rats were divided into seven groups (n = 6) including Normal control (NC), Diabetic control (DC), two standard control groups- Glibenclamide (GLIB) 5 mg/kg and Metformin (MET) 500 mg/kg, two bio-enhanced turmeric extract (BTE) treated groups (BTE-30 (30 mg/kg), BTE-60 (60 mg/kg)) and one regular turmeric extract treated (RTE) group RTE-30 (30 mg/kg). Treatment was given orally for 30 days. Streptozotocin (60 mg/kg) and Nicotinamide (110 mg/kg) were administered intraperitoneally to induce diabetes. Fasting blood glucose (FBG), oral glucose tolerance test at 60 min and 120 min (OG1 and OG2) were analysed at baseline and at the end of study on Day 29. FBG, fasting serum insulin, and concentration of curcumin and its derivatives present in pancreas were analysed at the end of study on Day 30. Turmeric extract treated groups showed significant (p < 0.05) blood glucose lowering effect, when compared with DC group. FBG, OG1 and OG2 readings were found significantly (p < 0.05) higher in RTE-30 treated group when compared with BTE-30 treated groups. Turmeric extracts showed improved beta-cell function, insulin sensitivity and decreased insulin resistance. BTE-30 had more pancreatic bioavailability of curcumin than RTE-30. Turmeric extracts demonstrated an antidiabetic effect in streptozotocin-nicotinamide induced type 2 diabetic Wistar rats. BTE extract was found to be an effective agent as compared to RTE in controlling hyperglycemia.

Sections du résumé

BACKGROUND BACKGROUND

Poor oral bioavailability of curcumin, the active ingredient in turmeric, has limited its therapeutic use in various diseases including diabetes mellitus (DM).

OBJECTIVE(S) OBJECTIVE

The present study was aimed at evaluating and comparing the antidiabetic activity as well as pharmacokinetic profile of two turmeric extracts.

MATERIALS AND METHODS METHODS

Rats were divided into seven groups (n = 6) including Normal control (NC), Diabetic control (DC), two standard control groups- Glibenclamide (GLIB) 5 mg/kg and Metformin (MET) 500 mg/kg, two bio-enhanced turmeric extract (BTE) treated groups (BTE-30 (30 mg/kg), BTE-60 (60 mg/kg)) and one regular turmeric extract treated (RTE) group RTE-30 (30 mg/kg). Treatment was given orally for 30 days. Streptozotocin (60 mg/kg) and Nicotinamide (110 mg/kg) were administered intraperitoneally to induce diabetes. Fasting blood glucose (FBG), oral glucose tolerance test at 60 min and 120 min (OG1 and OG2) were analysed at baseline and at the end of study on Day 29. FBG, fasting serum insulin, and concentration of curcumin and its derivatives present in pancreas were analysed at the end of study on Day 30.

RESULTS RESULTS

Turmeric extract treated groups showed significant (p < 0.05) blood glucose lowering effect, when compared with DC group. FBG, OG1 and OG2 readings were found significantly (p < 0.05) higher in RTE-30 treated group when compared with BTE-30 treated groups. Turmeric extracts showed improved beta-cell function, insulin sensitivity and decreased insulin resistance. BTE-30 had more pancreatic bioavailability of curcumin than RTE-30.

CONCLUSION CONCLUSIONS

Turmeric extracts demonstrated an antidiabetic effect in streptozotocin-nicotinamide induced type 2 diabetic Wistar rats. BTE extract was found to be an effective agent as compared to RTE in controlling hyperglycemia.

Identifiants

DOI: 10.1016/j.jaim.2021.04.010 PMID: 34353691 PMC: PMC8377175

pubmed: 34353691

pii: S0975-9476(21)00066-8

doi: 10.1016/j.jaim.2021.04.010

pmc: PMC8377175

pii:

doi:

Types de publication

Journal Article

Langues

eng

Pagination

474-479

Informations de copyright

Références

Diabetes Care. 2004 May;27(5):1047-53

pubmed: 15111519

Exp Biol Med (Maywood). 2012 May;237(5):481-90

pubmed: 22619373

Methods Find Exp Clin Pharmacol. 2009 May;31(4):249-61

pubmed: 19557203

Nutr Metab Cardiovasc Dis. 2011 Jul;21(7):526-33

pubmed: 20227862

Indian J Pharm Sci. 2008 Jul-Aug;70(4):445-9

pubmed: 20046768

J Pharmacol Exp Ther. 2008 Jul;326(1):196-208

pubmed: 18417733

Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110

pubmed: 31862752

J Tradit Complement Med. 2014 Apr;4(2):108-17

pubmed: 24860734

Bioorg Med Chem. 2014 Jan 1;22(1):435-9

pubmed: 24280069

Int J Biochem Cell Biol. 2009 Jan;41(1):40-59

pubmed: 18662800

Pharmacol Rep. 2012;64(1):129-39

pubmed: 22580529

Diabetol Metab Syndr. 2019 May 27;11:41

pubmed: 31149032

J Ethnopharmacol. 2011 Jan 27;133(2):480-3

pubmed: 20965240

Diabetes Care. 2012 Nov;35(11):2121-7

pubmed: 22773702

Biomed Res Int. 2014;2014:819065

pubmed: 24977161

Int J Mol Sci. 2019 Feb 27;20(5):

pubmed: 30818786

Planta Med. 1998 May;64(4):353-6

pubmed: 9619120

Diabetes Metab. 2011 Jun;37(3):179-88

pubmed: 21435930

Biochim Biophys Acta. 1998 Mar 6;1370(1):8-16

pubmed: 9518533

J Agric Food Chem. 2006 Nov 29;54(24):9055-62

pubmed: 17117790

J Nat Prod. 2011 Apr 25;74(4):664-9

pubmed: 21413691

Exp Physiol. 1996 Nov;81(6):927-33

pubmed: 8960699

Diabetes. 1998 Feb;47(2):224-9

pubmed: 9519717

Evid Based Complement Alternat Med. 2013;2013:636053

pubmed: 24348712